What is Pieris Pharmaceuticals Financial Strength?
Pieris Pharmaceuticals has the Financial Strength Rank of 5.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Pieris Pharmaceuticals has no long-term debt (1).
Pieris Pharmaceuticals's debt to revenue ratio for the quarter that ended in Dec. 2023 was 0.00.
As of today, Pieris Pharmaceuticals's Altman Z-Score is -10.83.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Competitive Comparison of Pieris Pharmaceuticals's Financial Strength
For the Biotechnology subindustry, Pieris Pharmaceuticals's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pieris Pharmaceuticals's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pieris Pharmaceuticals's Financial Strength distribution charts can be found below:
* The bar in red indicates where Pieris Pharmaceuticals's Financial Strength falls into.
Pieris Pharmaceuticals Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Pieris Pharmaceuticals's Interest Expense for the
months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the
months ended in Dec. 2023 was $-5.48 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.
Pieris Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 is
| Pieris Pharmaceuticals had no long-term debt (1). |
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Pieris Pharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.
2. Debt to revenue ratio. The lower, the better.
Pieris Pharmaceuticals's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Pieris Pharmaceuticals has a Z-score of -10.83, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
Warning Sign:
Altman Z-score of -10.83 is in distress zone. This implies bankruptcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pieris Pharmaceuticals (Pieris Pharmaceuticals) Business Description
Traded in Other Exchanges
Address
225 Franklin Street, 26th Floor, Boston, MA, USA, 02110
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm functions through the region of the United States.
Executives
| Ann Barbier |
director |
255 STATE STREET, C/O PIERIS PHARMACEUTICALS,INC., BOSTON MA 02109 |
| Peter A Kiener |
director |
40 GUEST STREET, BOSTON MA 02135 |
| Maya R. Said |
director |
C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109 |
| Matthew L Sherman |
director |
C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
| Christopher P Kiritsy |
director |
|
| Bvf I Gp Llc |
10 percent owner |
44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
| Bvf Ii Gp Llc |
other: See Explanation of Responses |
44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
| Bvf Gp Holdings Llc |
10 percent owner |
44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
| Shane Olwill |
officer: Chief Development Officer |
C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109 |
| Ahmed Mousa |
officer: Chief Business Officer |
255 STATE STREET, 9TH FLOOR, C/O PIERIS PHARMACEUTICALS, INC., BOSTON MA 02109 |
| Hitto Kaufmann |
officer: Chief Scientific Officer |
C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109 |
| Thomas Bures |
officer: Chief Financial Officer |
C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109 |
| Tim Demuth |
officer: Chief Medical Officer |
C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109 |
| Aquilo Capital Management, Llc |
10 percent owner |
ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO CA 94129 |
| Biotechnology Value Fund L P |
other: See Explanation of Responses |
44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PIRS has been successfully added to your